BIOMAT Database Logo BIOMAT Database Logo

A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. 1992

J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
AIDS Program, San Francisco General Hospital, CA.

HGP-30-KLH vaccine in alum at doses of 10, 25, 50, and 100 micrograms/kg administered intramuscularly at weeks 0, 4, and 10 appear well-tolerated clinically. Local pain at the injection site, appears to be the main clinical toxicity. Laboratory parameters are not affected by administration of the vaccine candidate except for perhaps mild urinalysis abnormalities at the highest dose. This vaccine candidate has no apparent immunotoxicity and does not appear to affect lymphocyte populations or T-cell functional studies. Low levels and transient antibodies develop in a minority of subjects early after immunization with the vaccine candidate. These responses were observed in the lowest dose range. Higher doses, and longer follow-up will be needed to confirm this observation. T-cell proliferative responses to KLH and KLH-HGP-30 are consistent and may not be dose dependent, but the proliferative responses are variable and more data need to be accumulated. Preliminary, there appears to be an HGP-30-induced CTL response of HGP-30-coated EBV-transformed autologous B cell lines. This study was approved under an IND for the California Department of Health Services' Food and Drug Branch. They have provided excellent support and regulatory guidelines for this project. Future work will extend and confirm these initial observations.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D006433 Hemocyanins Metalloproteins that function as oxygen transport proteins in the HEMOLYMPH of MOLLUSKS and ARTHROPODS. They are characterized by two copper atoms, coordinated with HISTIDINE residues, that reversibly bind a single oxygen molecule; they do not contain HEME groups. Hemocyanin,alpha-Haemocyanin,alpha-Hemocyanin,alpha-Hemocyanins,alpha Haemocyanin,alpha Hemocyanin,alpha Hemocyanins
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III

Related Publications

J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
September 1990, Proceedings of the National Academy of Sciences of the United States of America,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
June 1998, AIDS research and human retroviruses,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
May 1987, Proceedings of the National Academy of Sciences of the United States of America,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
May 1995, Cellular and molecular biology (Noisy-le-Grand, France),
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
January 1991, International journal of immunopharmacology,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus.
January 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
A phase I study of ampligen in human immunodeficiency virus-infected subjects.
October 1992, The Journal of infectious diseases,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
May 1999, Antimicrobial agents and chemotherapy,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
March 2003, The Journal of infectious diseases,
J O Kahn, and D P Stites, and J Scillian, and N Murcar, and R Stryker, and P A Volberding, and P H Naylor, and A L Goldstein, and P S Sarin, and V F Simmon
[Human immunodeficiency virus infection in seronegative subjects: myth or reality?].
May 1992, Medicina clinica,
Copied contents to your clipboard!